News
Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...
Participants who took tirzepatide (Zepbound) dropped an average of 50 pounds over 72 weeks. Those who took semaglutide ...
54m
Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback